BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11566603)

  • 21. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
    Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
    Kim YB; Han DP; Cao C; Cho MW
    Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates.
    Gómez CE; Navea L; Lobaina L; Dubed M; Expósito N; Soto A; Duarte CA
    Vaccine; 1999 May; 17(18):2311-9. PubMed ID: 10403600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.
    Laman JD; Schellekens MM; Lewis GK; Moore JP; Matthews TJ; Langedijk JP; Meloen RH; Boersma WJ; Claassen E
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):605-12. PubMed ID: 8369165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
    Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
    J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120.
    Schønning K; Bolmstedt A; Novotny J; Lund OS; Olofsson S; Hansen JE
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1451-6. PubMed ID: 9824323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
    Laisney IL; Strosberg AD
    Immunol Lett; 1999 Apr; 67(3):185-92. PubMed ID: 10369125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
    Zolla-Pazner S; Cohen SS; Krachmarov C; Wang S; Pinter A; Lu S
    Virology; 2008 Mar; 372(2):233-46. PubMed ID: 18061228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays.
    Moore JP; Cao Y; Conley AJ; Wyatt R; Robinson J; Gorny MK; Zolla-Pazner S; Ho DD; Koup RA
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):332-9. PubMed ID: 7510807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide.
    Vázquez Blomquist D; Green P; Laidlaw SM; Skinner MA; Borrow P; Duarte CA
    Viral Immunol; 2002; 15(2):337-56. PubMed ID: 12081016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.
    Fernández IM; Harmsen M; Benaissa-Trouw BJ; Stuij I; Puyk W; Meloen RH; Snippe H; Kraaijeveld CA
    Vaccine; 1998 Oct; 16(16):1531-6. PubMed ID: 9711800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
    Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
    Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines.
    Coëffier E; Girard M; Barré-Sinoussi F; Meignier B; Muchmore E; Fultz PN; LeClerc C
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1023-34. PubMed ID: 9718117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.